这是订阅内容的预览,通过你所在的机构访问
访问选项
订阅期刊
获得1年的完整期刊访问权限
119.00美元
每期只要9.92美元
所有价格均为净价格。
增值税稍后将在结帐时添加。
税务计算将在结账时完成。
买条
在ReadCube上获得时间限制或全文访问。
32.00美元
所有价格均为净价格。
改变历史
11月18日
超级标题已经更正。
参考文献
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM,等。髓系肿瘤和急性白血病的国际共识分类:整合形态学、临床和基因组数据。血。2022;140:1200-28。
郭丽娟,李志强,李志强,等。世界卫生组织血淋巴肿瘤分类第5版:髓系和组织细胞/树突状肿瘤。白血病。2022;36:1703-19。
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM,等。2016年世界卫生组织对髓系肿瘤和急性白血病分类的修订。血。2016;127:2391 - 405。
Patnaik MM, Tefferi A.慢性髓单核细胞白血病:2022年诊断、风险分层和管理的最新进展。美国血液病杂志。2020;95:97-115。
Binder M, Carr RM, Lasho TL, Finke CM, Mangaonkar AA, Pin CL,等。asxl1突变型慢性髓单核细胞白血病中顺式调控元件的癌基因表达和表观遗传重塑。Nat common . 2022;13:1434。
张志刚,张志刚,张志刚,等。RAS突变通过KMT2A-PLK1轴驱动增生性慢性髓单核细胞白血病。Nat common . 2021;12:2901。
李文杰,李志强,李志强,等。世卫组织2017年修订的慢性骨髓单核细胞白血病分类的验证。《血》2018;2:1807-16。
Patnaik MM, Timm MM, Vallapureddy R, Lasho TL, Ketterling RP, Gangat N,等。基于单核细胞亚群分析的流式细胞术可以准确地区分慢性骨髓单核细胞白血病与伴有单核细胞增多症的骨髓增生性肿瘤。血癌杂志,2017;7:e584。
Wagner-Ballon O, Bettelheim P, Lauf J, Bellos F, Della Porta M, Travaglino E,等。ELN iMDS流动工作组验证流式细胞术诊断慢性髓单核细胞白血病的单核细胞检测。细胞仪B临床细胞。2021。https://doi.org/10.1002/cyto.b.22054.
李志刚,李志刚,李志刚,李志刚,等。多参数流式细胞术在慢性髓单核细胞白血病中单核细胞亚群再划分的实际局限性。血癌杂志2019;9:65。
Solary E, Wagner-Ballon O, Selimoglu-Buet D.应用流式细胞仪和下一代测序技术诊断CMML。我们准备好了吗?临床血液醇最佳处方,2020;33:101134。
李志强,李志强,李志强,等。slan阳性非经典单核细胞消失诊断伴有炎症状态的慢性髓单核细胞白血病Haematologica。2019;haematol.2019.219782。
戈特利布J,马克森JE,乔治TI,泰纳JW。慢性中性粒细胞白血病和非典型CML的新遗传学:诊断和治疗的意义。血。2013;122:1707-11。
Mangaonkar AA, Swoboda DM, Lasho TL, Finke C, Ketterling RP, Reichard KK,等。无法分类的骨髓增生异常/骨髓增生性肿瘤的基因组分层:通过未分类进行分类。白血病。2021;35:3329 - 3333。
Bezerra ED, Lasho TL, Finke CM, Saliba AN, Elliott MA, Pardanani AD,等。CSF3R T618I突变型慢性髓系单核细胞白血病(CMML)定义了一种增殖型CMML亚型,该亚型富含ASXL1突变,并有不良后果。血癌J. 2021;11:54。
Mangaonkar AA, Swoboda DM, Coltro G, Lasho TL, Novotny PJ, Pophali P,等。骨髓增生异常/骨髓增生性肿瘤,不可分类(MDS/MPN-U)的临床病理特征、预后和治疗结果:梅奥诊所-莫菲特癌症中心对135名连续患者的研究。白血病。2020;34:656 - 61。
Patnaik MM, Hanson CA, Sulai NH, Hodnefield JM, Knudson RA, Ketterling RP,等。环铁母细胞百分比在世界卫生组织定义的骨髓增生异常综合征中与预后无关。血。2012;119:5674-7。
Palomo L, Meggendorfer M, Hutter S, Twardziok S, Adema V, Fuhrmann I,等。成人骨髓增生异常/骨髓增生性肿瘤的分子景观和克隆结构。血。2020;136:1851 - 62。
作者信息
作者及隶属关系
贡献
MP和JB写了初稿。所有作者都参与了手稿的写作、审查和编辑,并批准了最终版本的提交。
相应的作者
道德声明
相互竞争的利益
第一个MDS国际研讨会是由一个独立的科学指导委员会策划的。会议得到了吉利德、诺华、BMS、Syros、Geron和Karyopharm向Magdalen Medical/VJHemOnc提供的无限制教育赠款的支持。国际MDS联合会(icMDS);一个专注于临床前和临床MDS研究的国际专家小组,包括基础科学家、医学肿瘤学家/血液学家和病理学家,在2022年6月在佛罗里达州迈阿密举行的第一届MDS国际研讨会上召开。这份手稿是由一个核心小组起草的,由所有作者反复审查。会议发起者没有参与这份手稿的编写。所有作者都以个人身份开发和批准了这篇手稿,他们的观点不一定代表/反映他们的雇主。MMP、EP、SL、UP、DS、RB是WHO分类的作者。MS、RH和OO是ICC系统的作者。RK在MDS分类方面与WHO合作,但在MDS/MPN重叠肿瘤方面没有合作。 MMP has received research funding from Kura Oncology and Stemline Pharmaceuticals. AMZ is a Leukemia and Lymphoma Society Scholar in Clinical Research and received research funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Cardiff oncology, Incyte, Takeda, Novartis, Aprea, and ADC Therapeutics. AMZ participated in advisory boards, and/or had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Cardiff Oncology, Takeda, Ionis, Amgen, Janssen, Epizyme, Syndax, Gilead, Kura, Chiesi, ALX Oncology, BioCryst, Notable, Orum, and Tyme. AMZ served on clinical trial committees for Novartis, Abbvie, Gilead, BioCryst, Abbvie, ALX Oncology, Geron and Celgene/BMS. AD received consulting fees from Geron, Bristol-Myers Squibb, Novartis, Takeda, Geron, Taiho, CTI Biopharma, Gilead. RB conflicts of interest include: Aptose Biosciences - employment and equity, Gilead - data safety monitoring committees chair, Epizyme - data safety monitoring committee chair, BMS - honoraria, research funding, Takeda - research funding. RK consulted for Abbvie: Speaker Bureau, Advisory board; BMS: Research Grant, Advisory board; CTI biopharma: Speaker Bureau, Advisory board; Geron: Consultancy; Jazz: Speaker Bureau, Advisory board. Novartis: Advisory board; Pharma Essentia: Speaker Bureau, Advisory board; Servio: Speaker Bureau, Advisory board; Taiho: Advisory board. MS has participated in advisory Boards for BMS, Kurome and Novartis. JT has participated in advisory board for Kyropharm. TKK has received funding from Nextcure, that is not relevant to this manuscript. TKK is a consultant for Agenus and Immunobiome. MS consulted for Curis Oncology and Boston Consulting; served on the advisory board for Novartis, Kymera and Sierra Oncology; and participated in GME activity for Novartis, Curis Oncology, Haymarket Media and Clinical care options (CCO) DS has the following COI: Novartis (employment) and Bluebird and Arrowhead (Stock Ownership). MX participated in advisory boards and/or had a consultancy with and received honoraria from Seattle Genetics, Pure Marrow and Blueprint Medicines. PF has received honoraria and, as Groupe Francophone des Myelodysplasie’s chairperson, research support from: BMS/Celgene, Novartis, Janssen, Jazz, Abbvie. AN owns stocks in Amazon and Incyte. Employee at Incyte Pharmaceutical. SL has received research funding from Amgen and Astellas, has participated in advisory Boards for Abbvie and Guidepoint; has served as a consultant for Gerson Lehrman Group and QualWorld, and has stock ownership in Abbvie. OO has served on the advisory board of Bristol-Myers Squibb, Celgene, Novartis, Taiho and Kymera Therapeutics; serves on a DSMB for Threadwell Therapeutics and received research funding (institutional) from ABBVIE, Agios, Aprea, Astex, Astra Zeneca, Bristol Myers Squibb, Celgene, CTI, Daiichi, Incyte, Janssen, Kartos, Loxo, Novartis, NS-Pharma and Oncotherapy Sciences.
额外的信息
出版商的注意施普林格自然对出版的地图和机构从属关系中的管辖权主张保持中立。
权利和权限
关于本文
引用本文
帕特奈克,m.m.,扎伊丹,a.m.,帕德隆,E。et al。骨髓增生异常/骨髓增生性重叠肿瘤的分类模式差异。白血病36, 2934-2938(2022)。https://doi.org/10.1038/s41375-022-01754-3
收到了:
修改后的:
接受:
发表:
发行日期:
DOI:https://doi.org/10.1038/s41375-022-01754-3